Pacira BioSciences Files Patent Infringement Lawsuits to Protect EXPAREL® Against Generic Competitors
Pacira BioSciences Inc. has filed a patent infringement lawsuit against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd. regarding EXPAREL® in the U.S. District Court for the District of Delaware. This action triggers a 30-month stay of final FDA approval for the companies' ANDAs under the Hatch Waxman Act. EXPAREL is protected by 21 patents expiring in 2041 and 2044. Pacira aims to defend its intellectual property rights vigorously.
Pacira BioSciences Inc. has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd. The lawsuit concerns alleged infringement related to EXPAREL® (bupivacaine liposome injectable suspension). As a result, a 30-month stay of final FDA approval for the companies’ Abbreviated New Drug Applications (ANDAs) has been triggered under the Hatch Waxman Act. EXPAREL is currently protected by 21 patents listed in the FDA’s Orange Book, with expiration dates in 2041 and 2044. Pacira intends to vigorously defend its intellectual property rights. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592854-en) on November 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
